Millipore Sigma Vibrant Logo

IM11L Anti-TIMP-2 (Ab-1) Mouse mAb (T2-101)

Anti-TIMP-2 (Ab-1) Mouse mAb (T2-101) : FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: Anti-Tissue Inhibitor of Metalloproteinase-2

IM11L
  
Prix en cours de récupération
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
Maximum Quantity is
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
—
Demander le prix
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

       

      Contacter le Service Clients

      Aperçu

      Replacement Information

      Tableau de caractéristiques principal

      Host
      M
      Description
      Overview

      This product has been discontinued.





      Recognizes the ~21 kDa TIMP-2 protein.
      Catalogue NumberIM11L
      Brand Family Calbiochem®
      SynonymsAnti-Tissue Inhibitor of Metalloproteinase-2
      References
      ReferencesHöyhtyä, M., et al. 1994. Intl. J. Cancer. 56, 500.
      Cottam, D.W. and Rees, R.C. 1993. Intl. J. Oncol. 2 861.
      Stetler-Stevenson, W.G., et al. 1993. FASEB J. 7, 1434.
      Woessner, J.F. 1991. FASEB J. 5, 2145.
      Liotta, L.A. and Stetler-Stevenson, W.G. 1990. in Seminars in Cancer Biology, ed. M.M. Gottesman. Vol. 1, 99.
      Product Information
      DeclarationNot available for sale in Japan.
      FormLyophilized
      FormulationLyophilized from 20 mM ammonium bicarbonate solution, 100 µg (100 µg size) or 20 µg (20 µg size) BSA.
      Positive controlRecombinant TIMP-2 (Cat. No. PF021)
      PreservativeNone
      Applications
      Application ReferencesImmunoblotting, Immunoprecipitation, Frozen Sections, Original Clone Höyhtyä, M., et al. 1994. Int. J. Cancer. 56, 500.
      Key Applications Frozen Sections
      Immunoblotting (Western Blotting)
      Immunoprecipitation
      Not Paraffin Sections
      Application NotesFrozen Sections (see application references)
      Immunoblotting (5 µg/ml, see application references)
      Immunoprecipitation (see application references)
      Paraffin Sections (not recommended)
      Application CommentsAntibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogenhuman TIMP-2 purified from A2058 melanoma cells and recombinant TIMP-2 produced in a vaccinia virus expression system
      ImmunogenHuman
      CloneT2-101
      HostMouse
      IsotypeIgG₁
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Do not freeze Ok to freeze
      Special InstructionsWe recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of (100 µg) 100 µg/ml; or (20 µg) 20 µg/ml; product will be more stable if 0.1% sodium azide is included (do not add azide if antibody is to be used with viable cells). Lyophilized antibodies should be resuspended at 4°C with occasional gentle mixing for at least 2 h. For long-term storage, aliquot and freeze (-20°C) with 0.1% azide. Avoid freeze/thaw cycles.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      IM11L 0

      Documentation

      Anti-TIMP-2 (Ab-1) Mouse mAb (T2-101) Certificats d'analyse

      TitreNuméro de lot
      IM11L

      Références bibliographiques

      Aperçu de la référence bibliographique
      Höyhtyä, M., et al. 1994. Intl. J. Cancer. 56, 500.
      Cottam, D.W. and Rees, R.C. 1993. Intl. J. Oncol. 2 861.
      Stetler-Stevenson, W.G., et al. 1993. FASEB J. 7, 1434.
      Woessner, J.F. 1991. FASEB J. 5, 2145.
      Liotta, L.A. and Stetler-Stevenson, W.G. 1990. in Seminars in Cancer Biology, ed. M.M. Gottesman. Vol. 1, 99.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision27-August-2007 RFH
      SynonymsAnti-Tissue Inhibitor of Metalloproteinase-2
      ApplicationFrozen Sections (see application references)
      Immunoblotting (5 µg/ml, see application references)
      Immunoprecipitation (see application references)
      Paraffin Sections (not recommended)
      DescriptionPurified mouse monoclonal antibody (see application references). Recognizes the ~21 kDa TIMP-2 protein.
      BackgroundMatrix metalloproteinases (MMPs) are a family of enzymes that are responsible for the degradation of extracellular matrix components such as collagen, laminin and proteoglycans. In addition to sequence homology, all MMPs share the following characteristics: the catalytic mechanism is dependent upon a zinc ion at the active center, they cleave one or more extracellular matrix components, they are secreted as zymogens which are activated by removal of an approximately 10 kDa segment from the N-terminus, and their activity is regulated by endogenous inhibitors. These enzymes are involved in normal physiological processes such as embryogenesis and tissue remodeling and may play an important role in arthritis, periodontitis, and metastasis. The activation and activity of MMPs are regulated by a family of endogenous inhibitors, tissue inhibitors of metalloproteinase (TIMP). TIMP-2 (also called CSC-21K) is a 21 kDa glycoprotein that is expressed by a variety of cell types. It forms a non-covalent, stoichiometric complex with both latent and active MMPs. TIMP-2 shows a preference for MMP-2. TIMPs are capable of altering the metastatic potential of cancer cells and have been shown to inhibit invasion and metastasis in animal models.
      HostMouse
      Immunogen speciesHuman
      Immunogenhuman TIMP-2 purified from A2058 melanoma cells and recombinant TIMP-2 produced in a vaccinia virus expression system
      CloneT2-101
      IsotypeIgG₁
      Specieshuman, not mouse, not rat
      Positive controlRecombinant TIMP-2 (Cat. No. PF021)
      FormLyophilized
      FormulationLyophilized from 20 mM ammonium bicarbonate solution, 100 µg (100 µg size) or 20 µg (20 µg size) BSA.
      PreservativeNone
      CommentsAntibody should be titrated for optimal results in individual systems.
      Storage +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsWe recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of (100 µg) 100 µg/ml; or (20 µg) 20 µg/ml; product will be more stable if 0.1% sodium azide is included (do not add azide if antibody is to be used with viable cells). Lyophilized antibodies should be resuspended at 4°C with occasional gentle mixing for at least 2 h. For long-term storage, aliquot and freeze (-20°C) with 0.1% azide. Avoid freeze/thaw cycles.
      Toxicity Standard Handling
      ReferencesHöyhtyä, M., et al. 1994. Intl. J. Cancer. 56, 500.
      Cottam, D.W. and Rees, R.C. 1993. Intl. J. Oncol. 2 861.
      Stetler-Stevenson, W.G., et al. 1993. FASEB J. 7, 1434.
      Woessner, J.F. 1991. FASEB J. 5, 2145.
      Liotta, L.A. and Stetler-Stevenson, W.G. 1990. in Seminars in Cancer Biology, ed. M.M. Gottesman. Vol. 1, 99.
      Application referencesImmunoblotting, Immunoprecipitation, Frozen Sections, Original Clone Höyhtyä, M., et al. 1994. Int. J. Cancer. 56, 500.